Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.46 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.39 |
| ▸ | RBP4 | P02753 | 3/20 | 0.38 |
| ▸ | HTR5A | P47898 | 3/20 | 0.37 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17811354 | 0.87 | ESR1 (0.46) | ESR1ESR2EP300CREBBPPTGDR2 | |
| SCHEMBL17798326 | 0.86 | ESR1 (0.45) | ESR1ESR2EP300CREBBPRBP4 | |
| SCHEMBL17798666 | 0.84 | ESR1 (0.44) | ESR1ESR2EP300CREBBPPTGDR2 | |
| SCHEMBL17798518 | 0.79 | ESR1 (0.40) | ESR1ESR2EP300CREBBPRBP4 | |
| SCHEMBL17114724 | 0.79 | ESR1 (0.45) | ESR1ESR2EP300CREBBPPTGDR2 | |
| SCHEMBL17823126 | 0.79 | ESR1 (0.54) | ESR1ESR2EP300CREBBPPTGDR2 | |
| SCHEMBL506622 | 0.77 | ABHD6 (0.46) | ESR1ESR2PTGDR2ABHD6 | |
| SCHEMBL17823131 | 0.76 | ESR1 (0.51) | ESR1ESR2EP300CREBBPPTGDR2 | |
| SCHEMBL30814652 | 0.76 | ESR1 (0.45) | ESR1ESR2EP300CREBBPPTGDR2 | |
| SCHEMBL5753898 | 0.74 | SLC6A3 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2024-06-20 | — | — | US | disclosed |
| EP-3888689-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3735990-A1 | ANTIBODY DRUG CONJUGATES WITH CELL PERMEABLE BCL-XL INHIBITORS | Abbvie Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20200246323-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | ABBVIE INC. (US) | 2020-08-06 | — | — | US | disclosed |
| EP-3229844-B1 | ANTIBODY DRUG CONJUGATES WITH CELL PERMEABLE BCL-XL INHIBITORS | ABBVIE INC (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20190153107-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3468993-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3468598-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3468615-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017214456-A1 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| EP-3229844-A1 | ANTIBODY DRUG CONJUGATES WITH CELL PERMEABLE BCL-XL INHIBITORS | AbbVie Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170182179-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | ABBVIE INC. (US) | 2017-06-29 | — | — | US | disclosed |
| WO-2016094505-A1 | ANTIBODY DRUG CONJUGATES WITH CELL PERMEABLE BCL-XL INHIBITORS | ABBVIE INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | ESR1 553/4885ESR2 632/4885EP300 3648/4885 |
| US-20170182179-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | BCL2, BCL2L10, BAX | ESR1 3807/4885ESR2 2802/4885EP300 3871/4885 |
| US-20190153107-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | ESR1 553/4885ESR2 632/4885EP300 3648/4885 |
| US-20200246323-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | BCL2, BCL2L10, BAX | ESR1 3807/4885ESR2 2802/4885EP300 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.